GnRH Agonist Administration in the Luteal Phase of ICSI-ET Cycles
1 other identifier
interventional
570
1 country
1
Brief Summary
A single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles was reported to increase pregnancy and birth rates. This study was done to evaluate the reproducibility of previous findings.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Sep 2006
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2007
CompletedFirst Submitted
Initial submission to the registry
August 14, 2007
CompletedFirst Posted
Study publicly available on registry
August 15, 2007
CompletedAugust 15, 2007
August 1, 2007
August 14, 2007
August 14, 2007
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Ongoing pregnancy rate beyond 20 weeks
Secondary Outcomes (2)
Clinical pregnancy
Embryo implantation rate
Study Arms (2)
1
EXPERIMENTALGnRH agonist administration
2
PLACEBO COMPARATORSterile saline injection
Interventions
Single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
0.1 ml sterile saline subcutaneous injection on the 3rd day after embryo transfer
Eligibility Criteria
You may qualify if:
- Women undergoing embryo transfer following controlled ovarian hyperstimulation with a long GnRH agonist protocol, oocyte pick-up and ICSI.
- Embryo transfer performed on day 3.
You may not qualify if:
- Participation in another trial that was being conducted in our unit at the same time.
- Preimplantation genetic screening cycles.
- Day 5 embryo transfers.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Amerikan Hastanesi Tüp Bebek Merkezi
Istanbul, 34365, Turkey (Türkiye)
Related Publications (2)
Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, Mendoza C. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod. 2006 Oct;21(10):2572-9. doi: 10.1093/humrep/del173. Epub 2006 Aug 22.
PMID: 16926261BACKGROUNDAta B, Yakin K, Balaban B, Urman B. GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Hum Reprod. 2008 Mar;23(3):668-73. doi: 10.1093/humrep/dem421. Epub 2008 Jan 12.
PMID: 18192671DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Baris Ata, M.D.
The Assisted Reproduction Unit of the American Hospital of Istanbul
- STUDY DIRECTOR
Bulent Urman, M.D.
The Assisted Reproduction Unit of the American Hospital of Istanbul
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
August 14, 2007
First Posted
August 15, 2007
Study Start
September 1, 2006
Study Completion
July 1, 2007
Last Updated
August 15, 2007
Record last verified: 2007-08